Talquetamab

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 189 publications

Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience.

Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience.

Journal: Hematology (Amsterdam, Netherlands)
Published: September 01, 2026

Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study.

Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study.

Journal: Future oncology (London, England)
Published: August 30, 2026

Bispecific Antibodies Are Associated With Progressive Multifocal Leukoencephalopathy.

Bispecific Antibodies Are Associated With Progressive Multifocal Leukoencephalopathy.

Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: August 03, 2026

Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort.

Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort.

Journal: Leukemia & lymphoma
Published: July 28, 2026

Top advances of the year: Bispecific antibodies in early lines of therapy in multiple myeloma.

Top advances of the year: Bispecific antibodies in early lines of therapy in multiple myeloma.

Journal: Cancer
Published: July 07, 2026

Chari A, van de Donk NWCJ, Dholaria B, et al. Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study. Blood. 2025;146(24):2902-2913.

Chari A, van de Donk NWCJ, Dholaria B, et al. Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study. Blood. 2025;146(24):2902-2913.

Journal: Blood
Published: July 02, 2026

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; camizestrant for breast cancer, ivosidenib for biliary tract cancer, subcutaneous isatuximab and talquetamab plus teclistamab for multiple myeloma, isotretinoin for neuroblastoma, selpercatinib for pediatric RET-altered tumors, tafasitamab for lymphoma, and tislelizumab and durvalumab for gastric cancer.

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; camizestrant for breast cancer, ivosidenib for biliary tract cancer, subcutaneous isatuximab and talquetamab plus teclistamab for multiple myeloma, isotretinoin for neuroblastoma, selpercatinib for pediatric RET-altered tumors, tafasitamab for lymphoma, and tislelizumab and durvalumab for gastric cancer.

Journal: International journal of clinical oncology
Published: June 30, 2026

A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma.

A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma.

Journal: Current medical research and opinion
Published: June 25, 2026

Efficacy of Bispecific Antibodies in Relapsed or Refractory Multiple Myeloma With Extramedullary Disease: A Systematic Review and Meta-Analysis.

Efficacy of Bispecific Antibodies in Relapsed or Refractory Multiple Myeloma With Extramedullary Disease: A Systematic Review and Meta-Analysis.

Journal: Cureus
Published: June 24, 2026

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.

Journal: Oncology (Williston Park, N.Y.)
Published: June 22, 2026

Practical Management of Bispecific Antibodies in Multiple Myeloma.

Practical Management of Bispecific Antibodies in Multiple Myeloma.

Journal: JCO oncology practice
Published: June 17, 2026

Natural Taste Modulators and Microbiome-Aware Nutritional Support for Immunotherapy-Associated Dysgeusia: A Translational Perspective for Precision Supportive Cancer Care.

Natural Taste Modulators and Microbiome-Aware Nutritional Support for Immunotherapy-Associated Dysgeusia: A Translational Perspective for Precision Supportive Cancer Care.

Journal: Nutrients
Published: June 16, 2026
Showing 1-12 of 189

Last Updated: 09/26/2026